bortezomib + pembrolizumab + cisplatin

A combination therapy regimen consisting of bortezomib (a proteasome inhibitor), pembrolizumab (a PD-1 inhibitor immunotherapy), and cisplatin (a platinum-based chemotherapy agent). This combination leverages multiple mechanisms of action to target cancer cells, potentially overcoming resistance mechanisms and enhancing therapeutic efficacy through synergistic effects. Bortezomib is a proteasome inhibitor that has shown efficacy in multiple myeloma and other cancers[8]. Pembrolizumab is a PD-1 inhibitor immunotherapy drug that helps the immune system recognize and attack cancer cells[4][7]. Cisplatin is a platinum-based chemotherapy agent that damages DNA and prevents cancer cell replication[1][2]. While the search results don't specifically discuss all three drugs used together in a single regimen, they do provide information about various combinations involving these drugs. Pembrolizumab has been studied in combination with cisplatin for biliary tract cancer[4] and cervical cancer[5][7]. Bortezomib has been studied in combination with oncolytic reovirus therapy for multiple myeloma[8]. The combination approach represents a strategy to overcome resistance mechanisms and enhance therapeutic efficacy through synergistic effects. This approach aligns with the broader trend in oncology of using combination therapies to improve outcomes in difficult-to-treat cancers.